Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat colorectal cancer: immunotherapy combo trial launches

NCT ID NCT07281716

Recruiting now Disease control Sponsor: Dan Feng Source: ClinicalTrials.gov ↗

First seen Dec 24, 2025 · Last updated May 13, 2026 · Updated 17 times

Summary

This study tests a combination of two immunotherapy drugs (nadunolimab and toripalimab) in people with a type of advanced colorectal cancer that hasn't responded to standard chemotherapy. The goal is to see if the combination is safe and can shrink tumors or slow cancer growth. About 24 adults with microsatellite stable (MSS) colorectal cancer will receive treatment every 3 weeks for up to a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MICROSATELLITE STABLE COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC MICROSATELLITE STABLE COLORECTAL CARCINOMA